Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Sigma-Proligo Expands into Genopole® d'Evry Biopark

Published: Friday, October 20, 2006
Last Updated: Friday, October 20, 2006
Bookmark and Share
Sigma-Proligo provides researchers with high-quality oligonucleotides due to a high throughput synthesis platform.

Sigma-Proligo, a division of the Sigma-Aldrich group has announced it has acquired 2,000 sq. meters of office space in the heart of the Genopole® d'Evry biopark in the region of Paris. The official inauguration has took place on October 19 at 11:30 a.m.

Sigma-Proligo provides researchers throughout the world with high-quality oligonucleotides due to a high throughput synthesis platform.

With 65 employees in France, the majority of whom are researchers, Sigma-Proligo has expertise in nucleic acid synthesis and holds several key patents in siRNA gene silencing technology.

The new facility is expected to provide the capacity needed for the Company to advance the production of high-quality oligonucleotides in order to meet emerging needs within the bioscience research sector.

Sigma-Proligo develops protocols and methods in the field of oligonucleotides, and is one of four companies with the MIT license on siRNAs.

"The 'biotech' image of Genopole, as well as the offices and working environment perfectly adapted to our operations, have been the main reasons behind our expansion into Evry," said Khalil Arar, operations manager of Sigma-Aldrich Evry.

"The RNAi market has a predicted compound annual growth rate of 14%, and these new facilities are expected to provide Sigma-Proligo with the capacity to meet the increasing market demand for RNAi products."

"The facilities should also enable the Company to continue to supply customers with innovative products."

Thierry Mandon, President of Genopole, said, "A mature company moving onto the campus boosts the attractiveness of Evry-Corbeil as a business location, and demonstrates its credibility in the biotech sector."

Pierre Tambourin, CEO of Genopole, added, "This move will promote interactivity with our start-ups, which will profit from Sigma Proligo's knowledge, and our larger companies who need dynamic local links in order to pursue their development."

Marc Rebois, Director of SEM Genopole, the company that creates and manages the site's real estate and business accommodation resources, added, "Welcoming such a well-known company to Evry-Corbeil is a reward for our ongoing focus on truly biotech-dedicated real estate solutions, and it also constitutes recognition of our campus on the international level."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich Stockholders Approve Merck Acquisition
The transaction, expected to close mid-2015, remains subject to the satisfaction of the closing conditions set forth in the merger agreement, including regulatory approvals.
Monday, December 08, 2014
SAFC Expands Continuous Flow Capabilities
Sigma-Aldrich custom manufacturing services business unit, SAFC® Commercial, has installed a new commercial-scale continuous flow reactor at its Sheboygan, WI facility.
Wednesday, May 21, 2014
Sigma-Aldrich® Partners with Scripps Research Institute
The agreement marks first partnership of its kind between a research institution and reagents company.
Friday, July 19, 2013
Sigma Life Science to Distribute Olink Bioscience's Protein-Protein Interaction Assay
The products complement Sigma's antibody, RNAi and gene editing technologies.
Tuesday, February 12, 2013
Sigma-Aldrich Completes Acquisition of BioReliance
Sigma-Aldrich Corporation completes its acquisition of BioReliance Holdings, Inc. for $350 million in cash.
Wednesday, February 01, 2012
Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
Sigma Life Science announces that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at sageresearchmodels.com in late 2011.
Thursday, February 03, 2011
Sigma® Life Science Awarded Silver in Top Ten Innovations 2010
Company’s CompoZr® cell lines ranked second as The Scientist magazine unveils this year’s best life science innovations.
Monday, December 06, 2010
Plasticell Signs Technology Agreement with Sigma-Aldrich
Collaboration to produce novel turnkey solution for stem cell research.
Tuesday, November 30, 2010
Sigma® Life Science Enters Genetically Modified Cell Market
Sigma Life Science launches range of engineered cell lines exploiting CompoZr® zinc finger nuclease technology.
Monday, September 06, 2010
Sigma® Life Science and Switchgear Genomics to Co-Develop Simplified Novel MicroRNA Target Validation System
SwitchGear Genomics and Sigma’s lentiviral technology combined to simplify miRNA target validation, enabling researchers to investigate gene regulation.
Tuesday, August 10, 2010
Sigma-Aldrich Licenses from NeuroSurvival Technologies a Marker for Molecular Imaging of Apoptosis in Vivo
The marker, Apo-TRACE™, offers a breakthrough in advancing apoptosis-related research in a range of fields in biology and medicine.
Wednesday, February 27, 2008
Sigma-Aldrich Grants Pfizer Non-Exclusive Worldwide License to Use ddRNAi in Research Programs
The license enables Pfizer to undertake research activities throughout its global operations using ddRNAi technology.
Thursday, January 04, 2007
Sigma-Aldrich Announces Service Provider for WGA Technology
Sigma announces MOgene as its first service provider of the GenomePlex® Whole Genome Amplification technology.
Wednesday, May 31, 2006
Sigma-Aldrich Sponsors Full-Text Article on High Content Viral Library Screens
The authors reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 27, 2006
Scientists Publish Results on Sigma-Aldrich's shRNA Library in Cell
The publication reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 13, 2006
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!